Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck Serono Launches Geneva Spin-Off
by Rick Mullin
August 6, 2012
| A version of this story appeared in
Volume 90, Issue 32
Merck Serono has launched the first spin-off venture resulting from a $40 million program to employ researchers whose jobs are being cut with the closure of the company’s headquarters site in Geneva. Prexton Therapeutics, formed in a partnership with Eclosion, a biotech incubator in Geneva, will pursue neurodegenerative disease therapies based on Merck Serono’s R&D portfolio for Parkinson’s disease. Merck Serono will invest $2.6 million in the venture. The end of research operations in Geneva is eliminating about 500 jobs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X